CHRS Coherus BioSciences Inc.

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in a fireside chat presentation at the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025, at 11:50 a.m., Eastern time. A live audio webcast will be accessible through a link posted on the “Events and Presentations” section of the Coherus’ investor website: . A replay of the presentation will be available on this same website for approximately 90 days.

Coherus Contact Information:

For Investors:

Jodi Sievers

VP, Investor Relations & Corporate Communications



EN
24/02/2025

Underlying

CHRSCoherus BioSciences Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coherus BioSciences Inc.

 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Announces Repurchase of Approximately $170 Million of Converti...

Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes – Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture – REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company,” NASDAQ: CHRS) announced today that it has entered into privately negotiated transactions (the “Repurchases”) with certain holders (the “Holders”) of its 1.500% Convertible Senior Subordinated Notes due 2026 (the “Convertible Notes”), pursuant to which the Company agreed to repurchas...

April 1, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114...

Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), a commercial-stage innovative oncology company, today announced that an abstract highlighting interim data from its ongoing Phase 1 clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in combination with toripalimab in patients with ...

March 25, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial R...

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update – Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures –– UDENYCA® net revenue increased 62% year-over-year –– LOQTORZI® net revenue increased 29% quarter-over-quarter – – UDENYCA divestiture on track with Special Meeting of Shareholders taking place March 11, 2025; transaction expected to close late in the first quarter or early in the second quarter of 2025 – – Post divestiture expected cash of approximately $250 million, with cash runway e...

March 10, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results ...

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025 REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2024 financial results will be released after market close on Monday, March 10, 2025. Starting at 5:00 p.m. ET on March 10, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. Conference Call Information When: Monday, March 10, 2025, starting at 5:00 p.m....

March 3, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Management to Participate at the 45th Annual TD Cowen Health C...

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in a fireside chat presentation at the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025, at 11:50 a.m., Eastern time. A live audio webcast will be accessible through a link posted on the “Events and Presentations” section of the Coherus’ investor website: . A replay of the presentation will be available on this same website...

February 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch